Announcements Trials

Browse Landscape

Status

Sponsor Class

Study Type

Observational 1

Sponsor

Cancer Type

Conditions

Gastrointestinal Stromal Tumors 71 Sarcoma 12 Brain Neoplasms 10 Gliosarcoma 9 Glioblastoma 9 Neoplasm Metastasis 6 Glioma 6 Dermatofibrosarcoma 6 Oligodendroglioma 5 Central Nervous System Neoplasms 5 Astrocytoma 5 Leukemia, Myelogenous, Chronic, BCR-ABL Positive 4 Fibrosarcoma 4 Chordoma 4 Sarcoma, Synovial 3 Osteosarcoma 3 Neurofibrosarcoma 3 Neuroectodermal Tumors, Primitive, Peripheral 3 Neoplasms 3 Liposarcoma 3 Hemangiosarcoma 3 Glioma, Subependymal 3 Digestive System Neoplasms 3 Desmoid Tumors 3 Sarcoma, Endometrial Stromal 2 Recurrence 2 Primary Myelofibrosis 2 Piebaldism 2 Multiple Myeloma 2 Meningioma 2

Interventions

vandetanib 1 pazopanib 1 olverembatinib 1 lenvatinib 1 avapritinib 1 Surgical Procedures, Operative 1 Imatinib Mesylate 1 Coal Tar 1 6-chloro-9-(4-methoxy-3,5-dimethylpyridin-2-ylmethyl)-9H-purin-2-ylamine 1

Date Range

30 days 90 days 1 year All

Options

Has results Has announcements

Clinical Trials

1 trials

Recent Start date Enrollment

GIST × Imatinib Mesylate × Sarcoma × Clear all

NCT05895942 2023-06-09

EMMBKM

Xijing Hospital

GIST

Data powered by HemOnc (CC BY 4.0) Colophon ⚡